Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Search

Total 23 results found. Search for [ Lupin's revenue ]

Results 1 to 21 of 23
PB Jayakumar
May 17, 2019
Despite the pressure of business in the US, pharma major Lupin Limited recorded a 5.2 per cent rise in revenues to Rs 16,369.4 crore in FY19


BusinessToday.In
New Delhi, May 15, 2019
Net profit after exceptional items was up 141.4 per cent at Rs 606.60 crore during the financial year ended March 31, 2019; sales for Q4 FY2019 were up 8.7 per cent at Rs 4,325.90 crore compared to Rs 3,978.50 crore in Q4 FY2018;


BusinessToday.In
April 24, 2019
Except auto, all other sectoral indices ended in green backed up by gains in bank, IT, energy, telecom and finance.


PB Jayakumar
New Delhi, November 26, 2018
Market changes and increased regulatory oversight in the US have hurt Lupin, but India's third-biggest drug maker is making efforts to come back.


P.B. Jayakumar
New Delhi, April 30, 2018
Drug companies are moving up the value chain, transforming into complex generic manufacturers with high end R&D facilities.


E. Kumar Sharma
New Delhi, January 10, 2018
By following the strategy of doing a few things well, V.C. Nannapaneni has helped Natco Pharma carve out a space for itself.


P.B. Jayakumar
New Delhi, December 11, 2017
Margin erosion and regulatory hurdles are hitting Indian pharma companies hard in their biggest market.


E. kumar sharma
New Delhi, December 11, 2017
Indian pharma companies are facing strong headwinds, but they are also exploring every new opportunity to ensure a quick recovery.


PB Jayakumar
New Delhi, October 11, 2017
The acquisition of Symbiomix and the 'Solosec' franchise will help Lupin expand its women's health specialty business. Lupin will pay $50 million upfront and the remaining $100 million over the next five years.


E Kumar Sharma
New Delhi, August 17, 2017
On August 3rd, the largest generic company operating in the US, Teva Pharmaceutical Industries (Teva in quickspeak) put out results that arguably jolted the world of global generic medicines.


P.B. Jayakumar
Delhi, May 1, 2017
An air of urgency has been visible at the Mumbai headquarters of the second-largest Indian pharmaceutical company by sales, Lupin Ltd, for the past three to four years.


By E. Kumar Sharma,E Kumar Sharma
Delhi, October 29, 2016
Many major pharma stocks, seen as safe bets in the worst of times, have seen their market caps slip in the past year. Is pharma losing its sheen on the bourses?


P.B. Jayakumar and E. Kumar Sharma
Delhi, January 16, 2016
Since the past eight months the merged entity has been trading on the Bombay Stock Exchange, nervous investors have been asking two questions - is Shangvi's magic fading? Or, is the slump just a small hitch in Sun's glorious journey over the past one decade?


PB Jayakumar
December 25, 2015
Developed markets together now contribute 48% to Lupin's revenue (the bulk, no doubt, coming from the US) and emerging markets another 19%, while the domestic market's share has shrunk to 26 per cent from 31 per cent five years ago.


BT Online Bureau
New Delhi, May 14, 2015
For the quarter ended March 2015, the company registered consolidated net profit of Rs 547.01 crore, down 1.08 per cent, against Rs 553.01 crore in the corresponding quarter a year ago.


Tanvi Varma/Money Today
December 2, 2014
Looking at corporate results for the second quarter, it seems that business confidence is increasing. However, the same has not yet been reflected in investment demand.


Zeba Siddiqui
Mumbai, September 12, 2014
Salix will get an upfront payment from Lupin, and is entitled to additional payments contingent on meeting some sales milestones, the company said in a statement.


Arpita Mukherjee
August 23, 2014
Vinita Gupta took over the reins of Lupin in September 2013 and is now working towards achieving the Mumbai pharma company's projected revenue target of $5 billion by 2018.


PTI
New Delhi, April 23, 2014
Drug major Lupin has entered into a joint venture pact with Toyama-based Yoshindo Inc to form a new entity which will be responsible for development as well as obtaining marketing access for products in the Japanese market.


Suprotip Ghosh
December 23, 2013
Kamal K. Sharma came into Lupin after the company went through tough times. For one, the pharma firm was saddled with a massive Rs 500-crore debt. For another, it had missed the bus on global expansion while its peers such as Ranbaxy had started operations in the US.


PAGES 1 OF 2  12